Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis

Kidney International

Volumn 63, Issue 5, 2003, Pages 1868-1873

  Fadia, Amit ^a   Casserly, Liam F ^a   Sanchorawala, Vaishali ^a   Seldin, David C ^a   Wright, Daniel G ^a   Skinner, Martha ^a   Dember, Laura M ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute renal failure; AL amyloidosis; Autologous stem cell transplantation; Chemotherapy; Melphalan

Indexed keywords

CREATININE; MELPHALAN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SARGAMOSTIM;

ACUTE KIDNEY FAILURE; ADULT; AGED; AMYLOID LIGHT CHAIN AMYLOIDOSIS; ARTICLE; AUTOTRANSPLANTATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE COURSE; FEMALE; HEART AMYLOIDOSIS; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; INCIDENCE; KIDNEY AMYLOIDOSIS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0037406432     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00936.x     Document Type: Article

References (13)

1. KYLE RA, GERTZ MA, GREIPP PR, et al: A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336:1202-1207, 1997
2. SKINNER M, ANDERSON J, SIMMS R, et al: Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 100:290-298, 1996
3. COMENZO RL, VOSBURGH E, FALK RH, et al: Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 91:3662-3670, 1998
4. COMENZO RL, SANCHORAWALA V, FISHER C, et al: Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 104:553-559, 1999
5. SANCHORAWALA V, WRIGHT DG, SELDIN DC, et al: An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 28:637-642, 2001
6. DEMBER LM, SANCHORAWALA V, SELDIN DC, et al: Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. Ann Intern Med 134:746-753, 2001
7. LOLL LC, MOINPOUR CM, FEIGL P: Southwest Oncology Group (SWOG). J Natl Cancer Inst Monogr 20:83-85, 1996
8. ZAGER RA: Acute renal failure in the setting of bone marrow transplantation. Kidney Int 46:1443-1458, 1994
9. PARIKH CR, MCSWEENEY PA, KORULAR D, et al: Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int 62:566-573, 2002
10. MEROUANI A, SHPALL EJ, JONES RB, et al: Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int 50:1026-1031, 1996
11. HERGET-ROSENTHAL S, UPPENKAMP M, BEELEN D, et al: Renal complications of high-dose chemotherapy and peripheral blood stem cell transplantation. Nephron 84:136-141, 2000
12. ALIX JL, SWIERCZ P, SCHAERER R, et al: Nephrotoxicity of high-dose melphalan. Presse Med 12:575-576, 1983
13. ATKINSON K, BIGGS J, CONCANNON A, et al: Second marrow transplants for recurrence of haematological malignancy. Bone Marrow Transplant 1:159-166, 1986